Literature DB >> 29593892

Combining radiation plus immunotherapy to improve systemic immune response.

Taylor R Cushman1, Daniel Gomez1, Rachit Kumar1,2, Anna Likacheva1,2, Joe Y Chang1, Alex P Cadena1, Sebastien Paris3, James W Welsh1.   

Abstract

Over the past decade, the fields of oncology have made great strides in therapies. The development of new therapeutics and increased understanding of the role of the immune system in the development and treatment of cancer has led to increased collaboration between oncologic fields. Recent technologic advancements in radiation therapy (RT), including stereotactic beam radiation therapy (SBRT), have improved local control and offer an alternative to surgery for the control of oligometastatic disease. Immunotherapy has proven a promising therapeutic in the treatment of metastatic disease but treatment resistance remains a significant obstacle in the majority of patients. Together, radiation and immunotherapy offer potential to eliminate metastatic disease, reduce time to recurrence and improve overall survival. Major obstacles to these positive outcomes include high tumor burden, intratumoral heterogeneity, and the negative effects of tumor stroma, to name a few. Multimodality treatments are under heavy investigation. Promising data from clinical trials is emerging to highlight the value of RT in combination with immunotherapy. However, the mechanisms behind their synergistic effects remain to be fully elucidated. This review aims to highlight the existing literature and offers hypotheses to explain mechanisms behind the synergy of RT and immunotherapy.

Entities:  

Keywords:  Immunotherapy; abscopal; lung cancer; radiation therapy (RT); radiotherapy

Year:  2018        PMID: 29593892      PMCID: PMC5861265          DOI: 10.21037/jtd.2018.01.130

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  49 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

Authors:  Puneeth Iyengar; Brian D Kavanagh; Zabi Wardak; Irma Smith; Chul Ahn; David E Gerber; Jonathan Dowell; Randall Hughes; Ramzi Abdulrahman; D Ross Camidge; Laurie E Gaspar; Robert C Doebele; Paul A Bunn; Hak Choy; Robert Timmerman
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

3.  Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.

Authors:  R Hui; E B Garon; J W Goldman; N B Leighl; M D Hellmann; A Patnaik; L Gandhi; J P Eder; M-J Ahn; L Horn; E Felip; E Carcereny; R Rangwala; G M Lubiniecki; J Zhang; K Emancipator; C Roach; N A Rizvi
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

4.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

5.  Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly.

Authors:  Shervin M Shirvani; Jing Jiang; Joe Y Chang; James Welsh; Anna Likhacheva; Thomas A Buchholz; Stephen G Swisher; Benjamin D Smith
Journal:  JAMA Surg       Date:  2014-12       Impact factor: 14.766

Review 6.  Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

Authors:  Michael B Bernstein; Sunil Krishnan; James W Hodge; Joe Y Chang
Journal:  Nat Rev Clin Oncol       Date:  2016-03-08       Impact factor: 66.675

7.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

8.  Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy.

Authors:  Tommy Sheu; John V Heymach; Stephen G Swisher; Ganesh Rao; Jeffrey S Weinberg; Reza Mehran; Mary Frances McAleer; Zhongxing Liao; Thomas A Aloia; Daniel R Gomez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-09-09       Impact factor: 7.038

9.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.

Authors:  Jianjun Zhang; Junya Fujimoto; Jianhua Zhang; David C Wedge; Xingzhi Song; Jiexin Zhang; Sahil Seth; Chi-Wan Chow; Yu Cao; Curtis Gumbs; Kathryn A Gold; Neda Kalhor; Latasha Little; Harshad Mahadeshwar; Cesar Moran; Alexei Protopopov; Huandong Sun; Jiabin Tang; Xifeng Wu; Yuanqing Ye; William N William; J Jack Lee; John V Heymach; Waun Ki Hong; Stephen Swisher; Ignacio I Wistuba; P Andrew Futreal
Journal:  Science       Date:  2014-10-10       Impact factor: 47.728

10.  Hafnium oxide nanoparticles: toward an in vitro predictive biological effect?

Authors:  Julie Marill; Naeemunnisa Mohamed Anesary; Ping Zhang; Sonia Vivet; Elsa Borghi; Laurent Levy; Agnes Pottier
Journal:  Radiat Oncol       Date:  2014-06-30       Impact factor: 3.481

View more
  15 in total

Review 1.  Cancer Cell Metabolism: Implications for X-ray and Particle Radiation Therapy.

Authors:  Mathieu Sertorio; John P Perentesis; Ralph E Vatner; Anthony E Mascia; Yi Zheng; Susanne I Wells
Journal:  Int J Part Ther       Date:  2018-09-21

2.  Signals from SABR-COMET time to move on to phase III studies.

Authors:  Michael T Milano; Amit K Chowdhry; Joseph K Salama; Steven J Chmura
Journal:  Ann Transl Med       Date:  2019-12

Review 3.  Integrating nanomedicine into clinical radiotherapy regimens.

Authors:  Allison N DuRoss; Megan J Neufeld; Shushan Rana; Charles R Thomas; Conroy Sun
Journal:  Adv Drug Deliv Rev       Date:  2019-07-04       Impact factor: 15.470

Review 4.  SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.

Authors:  Yu Chen; Min Gao; Zhaoqin Huang; Jinming Yu; Xiangjiao Meng
Journal:  J Hematol Oncol       Date:  2020-07-28       Impact factor: 17.388

5.  Three discipline collaborative radiation therapy (3DCRT) special debate: I would treat all early-stage NSCLC patients with SBRT.

Authors:  Pranshu Mohindra; Amit Sawant; Robert J Griffin; Narottam Lamichhane; Erina Vlashi; Meng Xu-Welliver; Michael Dominello; Michael C Joiner; Jay Burmeister
Journal:  J Appl Clin Med Phys       Date:  2019-02-22       Impact factor: 2.102

Review 6.  Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment.

Authors:  Hari Menon; Rishab Ramapriyan; Taylor R Cushman; Vivek Verma; Hans H Kim; Jonathan E Schoenhals; Cemre Atalar; Ugur Selek; Stephen G Chun; Joe Y Chang; Hampartsoum B Barsoumian; Quynh-Nhu Nguyen; Mehmet Altan; Maria A Cortez; Stephen M Hahn; James W Welsh
Journal:  Front Immunol       Date:  2019-02-15       Impact factor: 7.561

Review 7.  MR-Guided Radiotherapy: The Perfect Partner for Immunotherapy?

Authors:  Juliane Hörner-Rieber; Sebastian Klüter; Jürgen Debus; Gosse Adema; Marleen Ansems; Marcel Verheij
Journal:  Front Oncol       Date:  2021-02-02       Impact factor: 6.244

Review 8.  Immunomodulatory Effects of Radiotherapy.

Authors:  Sharda Kumari; Shibani Mukherjee; Debapriya Sinha; Salim Abdisalaam; Sunil Krishnan; Aroumougame Asaithamby
Journal:  Int J Mol Sci       Date:  2020-10-31       Impact factor: 5.923

9.  Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma.

Authors:  Hampartsoum B Barsoumian; Rishab Ramapriyan; Ahmed I Younes; Mauricio S Caetano; Hari Menon; Nathan I Comeaux; Taylor R Cushman; Jonathan E Schoenhals; Alexandra P Cadena; Timothy P Reilly; Dawei Chen; Fatemeh Masrorpour; Ailin Li; David S Hong; Adi Diab; Quynh-Nhu Nguyen; Isabella Glitza; Renata Ferrarotto; Stephen G Chun; Maria Angelica Cortez; James Welsh
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

10.  Outcomes with multi-disciplinary management of central lung tumors with CT-guided percutaneous high dose rate brachyablation.

Authors:  Stephanie M Yoon; Robert Suh; Fereidoun Abtin; Drew Moghanaki; Scott Genshaft; Mitchell Kamrava; Alexandra Drakaki; Sandy Liu; Puja Venkat; Alan Lee; Albert J Chang
Journal:  Radiat Oncol       Date:  2021-06-07       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.